Vanguard Group Inc. Acquires 1,455,151 Shares of Dyne Therapeutics, Inc. $DYN

Vanguard Group Inc. lifted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 14.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 11,215,565 shares of the company’s stock after acquiring an additional 1,455,151 shares during the quarter. Vanguard Group Inc. owned approximately 0.08% of Dyne Therapeutics worth $219,376,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Arizona State Retirement System grew its position in shares of Dyne Therapeutics by 15.5% in the 4th quarter. Arizona State Retirement System now owns 31,416 shares of the company’s stock worth $614,000 after buying an additional 4,212 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Dyne Therapeutics in the 4th quarter worth about $282,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Dyne Therapeutics by 12.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,307 shares of the company’s stock worth $730,000 after buying an additional 3,993 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after purchasing an additional 1,440 shares in the last quarter. Finally, Elevate Capital Advisors LLC bought a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $472,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 83,219 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the completion of the sale, the director owned 7,962 shares of the company’s stock, valued at $144,749.16. This trade represents a 91.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,552,911 shares of company stock worth $29,694,469 over the last ninety days. 14.14% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on DYN shares. Morgan Stanley decreased their target price on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Chardan Capital reaffirmed a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 2nd. Finally, HC Wainwright decreased their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.14.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $17.61 on Friday. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. The business has a fifty day moving average price of $18.05 and a 200-day moving average price of $18.59. The company has a market capitalization of $2.91 billion, a PE ratio of -4.97 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.02). As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.